Scientific Online Resource System

Varna Medical Forum

Correlation between serum TSH and malignancy potential of thyroid nodules

Mira Siderova, Kiril Hristozov, Ivan Krasnaliev, Mila Boyadzieva, Yana Bocheva, Radoslav Radev, Rumen Nenkov

Abstract

Objectives:

Recent studies have reported that higher levels of TSH are associated with an increased incidence of thyroid malignancy in patients with nodular thyroid disease. However, different conditions may affect TSH concentration. The aim of our study was to correlate serum TSH levels in patients with thyroid nodules with cytological and histological results.

Materialsandmethods:

1483 consecutive patients (1339 women and 144 men) with nodular thyroid disease were evaluated by ultrasound-guided fine needle aspiration biopsy (FNAB) with cytological results classified as nondiagnostic, benign, follicular lesion, suspicious or malignant. Serum levels of TSHwere measured at presentation by chemiluminescent immunoassay. 390 of the patients were operated and final histology proved 83 carcinomas.

Results:

The overall sensitivity and specificity of FNAB in predicting malignancy were 90,32% and 81,11%, respectively. Mean TSH in cytologically benign nodules was 1,7032,569 mU/l, in follicular lesions 2,3934,119 mU/l, in suspicious nodules 2,3262,317 mU/l and in malignant on cytology nodules 3,0452,781 mU/l. Although in the reference range TSH levels in malignant cytologies were significantly higher that those in benign cases (p<0,0001). This relationship was confirmed among operated cases where mean preoperative TSH was significantly higher in histologically malignant than benign nodules (TSH 3,387 vs. 1,613 mU/l; p<0,0001). In order to eliminate the factors influencing TSH concentration, we excluded all patients with thyroid autonomy, Hashimoto`s thyroiditis (positive antibodies, US appearance, lymphocytic infiltration on histology) and those on levothyroxin or thyrostatic treatment. Among the rest of the patients, mean TSH value remained significantly lower in benign than malignant cases (1,370 vs. 2,805 mU/l; p<0,0001).

Conclusion:

Our results suggest a direct relationship between serum TSH and risk of malignancy in thyroid nodules both in cytological and histological series after excluding the influence of different thyroid diseases and medication.


Keywords

thyroid stimulating hormone (TSH); thyroid nodules; nodular goiter; thyroid carcinoma; malignancy

Full Text


References

Biondi B, Filetti S, Schlumberger M. Thyroid hormone therapy and thyroid cancer: a reassessment. Nature Clinical Practice. Endocrinology & Metabolism 2005; 1: 32-40

Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. Journal of Clinical Endocrinology and Metabolism 2006; 91: 4295-4301

Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P. The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential. Current Medicinal Chemistry 2010; 17(30):3449-3461

Datta RV, Petrelli NJ, Ramzy J. Evaluation and management of incidentally discovered thyroid nodules. Surgical oncology 2006; 15: 33-42

Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F et al. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocrine-Related Cancer 2009; 16: 1251-1260

Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F et al.L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients. Endocrine-Related Cancer, 2010, 17: 231-239

Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012; 97(4):1134-45

Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedüs L, Vitti P. AACE/AME/ETA Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2010; 16 (Suppl 1): 1-42

Haugen BR, Alexander EK, Bible KC et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26 (1): 1-133

Haymart MR, Repplinger DJ, Leverson DJ, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. Journal of Clinical Endocrinology and Metabolism, 2008, 93: 809-814

Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. ClinicalEndocrinology 2009 713 434-439

Hegedüs L., S.J. Bonnema, F.N. Bennedbaek. Management of simple nodular goiter: current status and future perspectives. Endocrine Reviews 24, 2003, 1, 102-132

Jin J, Machekano R, McHenry CR. The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease. American Journal of Surgery 2010; 199: 294-298

Maia F.R., Wittmann D.E. Thyroid nodule management: clinical, ultrasound and cytopathological parameters for predicting malignancy. Clinics 67, 2012, 8, 945-954

McLeod DSA, Watters KF, Carpenter AD, Ladenson PW, Cooper DS, Ding EL. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J ClinEndocrinolMetab, August 2012, 97(8):2682-2692

Rago T, Fiore E, Scutari M, Santini F, Di Coscio G, Romani R et al. Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. European Journal of Endocrinology, 2010, 162: 763-770

Siderova M, Hristozov K. The association between Hashimoto's thyroiditis and thyroid cancer - myth or reality? Endocrinologia, 2015, 20(4):189-196

Sipos JA, Mazzaferri EL. The therapeutic management of differentiated thyroid cancer. Expert Opinion on Pharmacotherapy 2008; 9:2627-2637

Zafon C, Obiols G, Baena JA, Castellvi J, Dalama B, Mesa J. Preoperative thyrotropin serum concentrations gradually increase from benign thyroid nodules to papillary thyroid microcarcinomas then to papillary thyroid cancers of larger size. Hindawi Publishing Corporation Journal of Thyroid Research Volume 2012, Article ID 530721, doi:10.1155/2012/530721


Refbacks

Font Size


|